A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Trial Profile

A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Fludarabine
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Jan 2017 Planned primary completion date changed from 1 Feb 2020 to 4 Feb 2020.
    • 14 Jun 2016 Planned number of patients changed from 33 to 32.
    • 06 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top